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Abstract
Spondyloarthritis may be increasingly present in older patients as life expectancy increases. We investigated clinical differences
between early-onset and late-onset spondyloarthritis in Japan.
We retrospectively reviewed 114 patients consecutively diagnosed with spondyloarthritis. The clinical course of each patient was
observed for ≥1 year. We defined early-onset and late-onset spondyloarthritis as <57 or ≥57 years at a median age of this study
group, respectively. We compared clinical characteristics between these 2 groups.
Disease duration was significantly shorter before diagnosis in the late-onset group (P< .01). Inflammatory back pain (IBP) was
significantly more common in the early-onset group (P< .01), whereas dactylitis frequency was significantly higher in the late-onset
group. Significantly more patients with early-onset spondyloarthritis were human leukocyte antigen (HLA) B27-positive (P< .01).
Articular synovitis, particularly of the wrist, was significantly more common on power Doppler ultrasound (PDUS) in the late-onset
group (P< .01). Tenosynovitis or peritendinitis, particularly in the finger and wrist flexors were also more frequent in the late-onset
group (P< .001 and P< .05, respectively). Enthesitis of the finger collateral ligament and lateral collateral ligament were significantly
more common in the late-onset group (both P< .05). Multiple logistic regression analysis revealed that, comparatively, IBP was
significantly and independently much more likely to occur in the early-onset group.
The patients with late-onset spondyloarthritis had a lower frequency of IBP and HLA B27 and a higher frequency of dactylitis and
PDUS findings in peripheral involvement.
Abbreviations: AS = ankylosing spondylitis, ASAS = assessment of SpondyloArthritis International Society classification, axSpA
= axial SpA, EOSpA= early-onset SpA, GS= grayscale, HLA= human leukocyte antigen, IBD= inflammatory bowel disease, LOSpA
= late-onset SpA, MRI=magnetic resonance imaging, MRI=magnetic resonance imaging, NA= not available, PD= power Doppler,
PDUS = power Doppler ultrasound, PMR = polymyalgia rheumatica, PsA = psoriatic arthritis, pSpA = peripheral SpA, RA =
rheumatoid arthritis, ReA = reactive arthritis, RS3PE = remitting seronegative symmetrical synovitis with pitting edema, SpA =
spondyloarthritis, US = ultrasound, uSpA = undifferentiated SpA.
Keywords: early-onset spondyloarthritis, late-onset spondyloarthritis, peripheral spondyloarthritis, spondyloarthritis
1. Introduction
Spondyloarthritis (SpA) diseases share similar clinical manifes-
tations, such as involvement of sacroiliac joints, spine, peripheral
joints, and skin as well as mucosal involvement. In the 1970s,
Moll and Wright established the concept of a group of
interrelated disorders termed seronegative spondyloarthriti-
des.[1] The European Spondylarthropathy Study Group (ESSG)
established the ESSG criteria for a group of diseases known as
SpA, which included ankylosing spondylitis (AS), psoriatic
arthritis (PsA), inflammatory bowel disease (IBD)-related
arthritis, reactive arthritis (ReA), and undifferentiated SpA
(uSpA), an entity that does not fit in any of the other
classifications.[2,3] Additionally, the assessment of SpondyloAr-
thritis International Society (ASAS) grouped SpA into 2
categories based on the predominant clinical presentation: axial
SpA (axSpA) or peripheral SpA (pSpA).[4–6] Although conven-
tional radiography reflects the structural consequences of the
inflammatory process, magnetic resonance imaging (MRI) can
detect early inflammatory changes before the appearance of
sacroiliitis on X-ray.[7,8] Non-radiographic axSpA developed by
the ASAS is the term used for an axSpA without sacroiliitis seen
on X-ray.[5]
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The frequency of human leukocyte antigen (HLA) B27-
positivity, which is associated with SpA, varies substantially
among individuals of different countries.[9] In Japan, the
prevalence of HLA B27 is 0.3% in the general population,[10]
which is much lower than that in other countries. However, the
frequency of HLA B27-positivity in Japanese SpA patients has
not been clarified.
Onset of SpA in older adults has been considered rare,[11] but
cases are increasingly reported.[12–14] The number of such
patients is expected to increase with longer life expectancy.[11,13–
16] Later- or late-onset SpA (LOSpA)[11,13,15,16] has not been
precisely defined, but most studies have used onset at 50 years or
older to classify such patients.[13] Previous studies that assessed
areas with high HLA B27 prevalence revealed differences
between characteristics of early-onset SpA (EOSpA) and
LOSpA.[11,14,15] However, the findings in LOSpA have not yet
been reported for Japan, a super-aging society.
In the present study, we compared the clinical profiles of
patients with EOSpA or LOSpA to describe the clinical
characteristics of LOSpA in Japan.
2. Materials and methods
2.1. Patients
This was a single-center retrospective cohort study approved by
the medical ethics committee of Japan Community Healthcare
Organization Isahaya General Hospital. The study population
consisted of 114 Japanese patients with SpA who were managed
between April 2009 and December 2017 at our institution. The
present study included both incident and prevalent cases. The
clinical course of each patient was observed for ≥1 year. A
definitive diagnosis of SpA was made by a Japan College of
Rheumatology (JCR)-certified rheumatologist (KF, AM, MM,
and TT) after excluding other rheumatic diseases by evaluating
the following items: medical history, physical examination,
laboratory findings, imaging findings, SpA classification criteria,
and therapeutic response. Inflammatory back pain (IBP) was
defined by the Berlin criteria.[17] Enthesis tenderness was
evaluated on clinical examination according to the Leeds Enthesis
Index[18] and the Spondyloarthritis Research Consortium of
Canada.[19] The inclusion criteria were any of the various sets of
SpA classification criteria that include the following: Amor,[2]
ESSG,[3] ASAS criteria for axSpA,[5] ASAS criteria for pSpA,[6]
and modified New York[20] criteria. Thus, all patients satisfied 1
or more of the SpA classification criteria. We defined radio-
graphic sacroiliitis as grade ≥2 bilaterally or grade 3-4
unilaterally on pelvic X-ray according to the modified New
York criteria.[20] In cases wherein radiographic sacroiliitis was
uncertain or there was persistent IBP, MRI of the SIJs was
performed. This was defined in the MRI as the presence of active
inflammatory lesions such as bone marrow edema or osteitis as
proposed by the ASAS MRI working group.[21] An expert
radiologist (MU) interpreted the MRIs. We also performed
power Doppler ultrasound (PDUS) assessments in patients with
peripheral symptoms. These assessments were done by JCR-
registered sonographers (YE, KF). Systematic multiplanar gray
scale (GS) and power Doppler (PD) examinations of joints,
tendons, and entheses were performed with a LOGIQ S8
ultrasound machine (GE Healthcare, Wauwatosa, WI) using a
multifrequency linear transducer (4–15MHz). We assessed
articular synovia by PDUS at the wrists and the metacarpopha-
langeal (MCP), proximal interphalangeal (PIP), knee, and ankle
joints bilaterally. Articular synovitis on PDUS was defined as GS
and PD findings in the synovium. Tendons and tendon sheaths
were also bilaterally assessed by PDUS at the extensor and flexor
tendon sheaths of the wrist, periextensor tendon and flexor
tendon sheaths of the finger, and tibialis posterior tendon sheaths.
Tenosynovitis and peritendinitis were defined as GS and PD
positivity of the tendon sheath or peritendon. Finally, we assessed
the entheseal insertions bilaterally with US at the finger collateral
ligaments, common extensor tendons on the lateral epicondyle of
elbow, quadriceps tendon on the superior pole of the patella,
proximal patellar ligament on the inferior pole of patella, distal
patellar ligament on the tibial tuberosity, medial collateral
ligament on the medial femoral condyle, lateral collateral
ligament on the lateral femoral condyle, and Achilles tendon
on the calcaneus. Enthesitis was defined on PDUS as a PD signal
with or without structural abnormalities of the enthesis. Patients
who did not have medical records including onset of disease,
HLA-B antigen, and fulfillment of the SpA criteria were excluded.
Further, those who did not have a definitive diagnosis and were
diagnosed as palmoplantar pustular arthritis and synovitis, acne,
pustulosis, hyperostosis, and osteitis (SAPHO) syndrome were
excluded.
The definition of age at onset associated with LOSpA has not
been consistent among previous reports. In this study, we defined
EOSpA and LOSpA as <57 or ≥57 years at a median age of this
study group, respectively. We compared clinical manifestations
and laboratory and imaging findings between these 2 groups.
2.2. Statistical analysis
The demographic and clinical characteristics were comparedwith
Fisher exact test for discrete variables and with Wilcoxon test for
continuous variables. The Kruskal–Wallis test followed by Dunn
multiple comparisons test was used to compare the 2 groups.
To independently determine factors associated with LOSpA,
we performed multiple logistic regression analysis, using
variables with P-values of <.05 on univariate analysis. Statistical
analyses were performed with JMP pro 13.0 software (SAS
Institute, Cary, NC). All reported P-values are 2-sided. A P-value
of <.05 was considered statistically significant.
3. Results
3.1. Patient characteristics and diagnosis
A total of 114 patients including those with EOSpA (n=55) and
LOSpA (n=59) were reviewed in this study. Among these
patients (median age, 57.0 years), 78 (68.4%) were diagnosed as
uSpA, 16 (14%) as PsA, 11 (9.7%) as AS, 6 (5.3%) as IBD-
related arthritis, 2 (1.8%) as nr-axSpA, and 1 (0.9%) as ReA. The
median age at disease onset was 48.0 years for the EOSpA group
and 72.0 years for the LOSpA group (Table 1). Disease duration
at diagnosis was significantly shorter in the LOSpA group. There
was no significant difference in terms of sex and family history of
SpA between the 2 groups. As a definitive diagnosis, uSpA was
common in both groups, and there was no significant difference
in the proportion between the 2 groups.
3.2. Clinical features and laboratory characteristics
We found no significant differences in terms of the presence of
enthesis tenderness, arthritis of the lower limbs, or uveitis.
However, IBP was significantly less common in the LOSpA
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group, whereas dactylitis was significantly more common in the
LOSpA group (Table 2). The RF positivity was 11.4% among all
patients, and the average of the RF titer was 28.2 IU/ml (normal
range; 0–15IU/ml) among RF-positive patients with SpA. None
of these patients met the 2010ACR/EULAR classification criteria
for rheumatoid arthritis (RA)[22] even after accounting for the
number of synovitis in PDUS. The groups did not differ in terms
of positivity for rheumatoid factor or anti-citrullinated protein
antibody at diagnosis. The prevalence of HLA-B27was 14 of 114
(12.3%) and 8 of 11 (72.7%) in all patients with SpA patients and
those with AS, respectively. Significantly fewer patients with
LOSpA were HLA B27-positive than those with EOSpA.
Although all patients with AS in the EOSpA group were HLA
B27-positive, only 2 of 5 (40%) patients with AS in the LOSpA
group were HLA B27 positive (data not shown).
3.3. Fulfillment of SpA criteria
The Amor criteria were most commonly fulfilled in both groups
(Table 3). None of the patients with LOSpA fulfilled the ASAS
Table 1
Patient characteristics and clinical diagnosis of patients with EOSpA and LOSpA (univariate analysis).
Variables All (n=114) EOSpA (n=55) LOSpA (n=59) P-value
∗
Patient characteristics
Age at onset, yr 57.0 (48.0–72.0) 48.0 (32.0–51.0) 72.0 (65.0–77.0) <.001
Age at diagnosis, yr 61.0 (50.0–75.0) 50.0 (43.0–55.0) 74.0 (68.0–79.0) <.001
Disease duration, yr 1.0 (0.3–6.0) 2.0 (0.25–10.0) 0.5 (0.2–2.0) .004
Male sex 74 (64.9%) 39 (70.9%) 35 (59.3%) .24
Family history of SpA 4 (3.5%) 3 (5.5%) 1 (1.7%) .35
Clinical diagnosis
AS 11 (9.7%) 6 (10.9%) 5 (8.5%) .76
nr-axSpA 2 (1.8%) 2 (3.6%) 0 (0.0%) .23
PsA 16 (14.0%) 9 (16.4%) 7 (11.9%) .59
IBD-related arthritis 6 (5.3%) 3 (5.5%) 3 (5.1%) 1.00
ReA 1 (0.9%) 1 (1.8%) 0 (0.0%) .48
uSpA 78 (68.4%) 34 (61.8%) 44 (74.6%) .16
Data are reported as median (interquartile range) or number (percentage).
∗
P-values refer to comparisons between patients with EOSpA and LOSpA. Fisher exact test or Mann–Whitney U-test was used, as appropriate.
AS= ankylosing spondylitis, EOSpA= early-onset SpA, IBD= inflammatory bowel disease, LOSpA= late-onset SpA, nr-axSpA=non-radiographic axial SpA, PsA=psoriatic arthritis, ReA= reactive arthritis,
SpA= spondyloarthritis, uSpA=undifferentiated SpA.
Table 2
Clinical features and laboratory characteristics of patients with EOSpA and LOSpA (univariate analysis).
Variables All (n=114) EOSpA (n=55) LOSpA (n=59) P-value
∗
Clinical features
Inflammatory back pain 50 (43.9%) 32 (58.2%) 18 (30.5%) .004
Tenderness of enthesis 93 (81.6%) 43 (78.2%) 50 (84.8%) .47
Dactylitis 48 (42.1%) 14 (25.5%) 34 (57.6%) <.001
Arthritis of lower limbs 89 (78.1%) 42 (76.4%) 47 (79.7%) .82
Uveitis 4 (3.5%) 4 (7.3%) 0 (0.0%) .051
Laboratory findings
RF (+) 13 (11.4%) 6 (10.9%) 7 (11.9%) 1.00
ACPA (+) 1 (1.8%) 1 (1.7%) 0 (0.0%) .48
HLA B27 (+) 14 (12.3%) 12 (21.8%) 2 (3.4%) .003
Data are reported as number (percentage) or median (interquartile range, number).
∗
P-values refer to comparisons between patients with EOSpA and LOSpA. Fisher exact test or Mann–Whitney U-test was used, as appropriate.
ACPA=anti-citrullinated protein antibody, EOSpA= early-onset SpA, HLA=human leukocyte antigen, LOSpA= late-onset SpA, RF= rheumatoid factor, SpA= spondyloarthritis.
Table 3
Patients fulfilling each set of SpA criteria (univariate analysis).
Variables All (n=114) EOSpA (n=55) LOSpA (n=59) P-value
∗
Amor criteria 100 (87.7%) 47 (85.5%) 53 (89.8%) .57
ESSG criteria 77 (67.5%) 41 (74.6%) 36 (61.0%) .16
Axial ASAS criteria 11 (9.7%) 11 (20.0%) 0 (0.0%) <.001
Peripheral ASAS criteria 88 (77.2%) 40 (72.7%) 48 (81.4%) .37
mNY criteria 13 (11.4%) 6 (10.9%) 7 (11.9%) 1.00
Data are reported as number (percentage).
∗
P-values refer to comparisons between patients with EOSpA and LOSpA. Fisher exact test was used.
ASAS=assessment of SpondyloArthritis International Society classification, EOSpA= early-onset SpA, ESSG=European Spondylarthropathy Study Group, LOSpA= late-onset SpA, mNY=modified New York,
SpA= spondyloarthritis.
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criteria for axSpA as these criteria do not apply to individuals
over 45 years of age at onset. There were no significant
differences in terms of the number of patients fulfilling each set of
SpA criteria between the groups.
3.4. Imaging characteristics
There was no significant difference in the frequency of sacroiliitis
on X-ray or MRI between the 2 groups (Table 4). Peripheral
involvement by PDUS was evaluated in 47 patients with EOSpA
and in 56 with LOSpA. On PDUS, articular synovitis was
detected in 58 of 103 (56.3%) in all patients, and the median
number of synovitis was 1.0. Synovitis of at least 1 joint was
significantly more common in the LOSpA group than in the
EOSpA group, particularly in the wrist. Bone erosion was not
detected in PIP, MCP, and wrist joints of all patients except for 1
patient with PsA. Tenosynovitis or peritendinitis was detected in
67 of 103 (65.1%) in all patients, and the median number of
tenosynovitis or peritendinitis was 1.0. Tenosynovitis or
peritendinitis of at least 1 site was significantly more common
in the LOSpA group than in the EOSpA group, particularly in the
finger flexor tenosynovitis and wrist flexor tenosynovitis.
Enthesitis was detected in 91 of 98 (92.9%) patients, and the
median number of enthesitis was 2.0. In both EOSpA and
LOSpA, enthesitis was the most frequent finding in PDUS.
Enthesitis of finger collateral ligament and lateral collateral
ligament were also significantly more prevalent in the LOSpA
group.
3.5. Independent factors associated with age at onset
We selected factors that varied significantly between the 2 groups
in the univariate analysis and subjected them to multivariate
logistic regression analysis. Only 1 factor was independently
associated; IBP was more likely to be associated with the EOSpA
group compared with the LOSpA group (Table 5).
Table 4
Imaging characteristics in patients with EOSpA and LOSpA (univariate analysis).
Variables All (n=114) EOSpA (n=55) LOSpA (n=59) P-value
∗
X-ray findings
Sacroiliitis 20/106 (18.9%) 8/48 (16.7%) 12/58 (20.7%) .63
MRI findings
Sacroiliitis 10/63 (15.9%) 5/31 (16.1%) 5/32 (15.6%) 1.00
PDUS findings
Articular synovitis 58/103 (56.3%) 21/47 (44.7%) 37/56 (66.1%) .046
Number of synovitis 1.0 (0.0–2.0, n=103) 0.0 (0.0–1.0, n=47) 1.0 (0.0–2.0, n=56) .023
PIP synovitis 6/103 (5.8%) 4/47 (8.5%) 2/56 (3.6%) .41
MCP synovitis 17/103 (16.5%) 7/47 (14.9%) 10/56 (17.9%) .79
Wrist synovitis 39/103 (37.9%) 11/47 (23.4%) 28/56 (50.0%) .008
Knee synovitis 25/100 (25.0%) 7/45 (15.6%) 18/55 (32.7%) .064
Ankle synovitis 5/97 (5.2%) 2/44 (4.6%) 3/53 (5.7%) 1.00
Bone erosion 1/103 (1.0%) 1/47 (2.1%) 0/56 (0.0%) .46
Tenosynovitis or peritendinitis 67/103 (65.1%) 25/47 (53.2%) 42/56 (75.0%) .024
Number of tenosynovitis or peritendinitis 1.0 (0.0–3.0, n=103) 1.0 (0.0–2.0, n=47) 2.0 (1.0–3.0, n=56) .002
Finger periextensor tendinitis 13/103 (12.6%) 5/47 (10.6%) 8/56 (14.3%) .77
Finger flexor tenosynovitis 46/103 (44.7%) 12/47 (25.5%) 34/56 (60.7%) <0.001
Wrist extensor tenosynovitis 30/103 (29.1%) 10/47 (21.3%) 20/56 (35.7%) .13
Wrist flexor tenosynovitis 36/103 (35.0%) 10/47 (21.3%) 26/56 (46.4%) .012
Tibialis posterior tenosynovitis 26/98 (26.5%) 11/44 (25.0%) 15/54 (27.8%) .82
Enthesitis 91/98 (92.9%) 38/43 (88.4%) 53/55 (96.4%) .23
Number of enthesitis 2.0 (1.0–3.0, n=99) 2.0 (1.0–3.0, n=44) 3.0 (2.0–4.0, n=55) <.001
Finger collateral ligament 48/92 (52.2%) 15/40 (37.5%) 33/52 (63.5%) .02
Common extensor tendon 23/90 (25.6%) 7/40 (17.5%) 16/50 (32.0%) .15
Quadriceps tendon 42/98 (42.9%) 16/43 (37.2%) 26/55 (47.3%) .41
Proximal patellar ligament 6/97 (6.2%) 3/42 (7.1%) 3/55 (5.5%) 1.00
Distal patellar ligament 28/97 (28.9%) 8/42 (19.1%) 20/55 (36.4%) .074
Medial collateral ligament 49/97 (50.5%) 18/42 (42.9%) 31/55 (56.4%) .22
Lateral collateral ligament 34/97 (35.1%) 9/42 (21.4%) 25/55 (45.5%) .018
Achilles tendon 10/98 (10.2%) 3/44 (6.8%) 7/54 (13.0%) .50
Data are reported as number (percentage) or median (interquartile range, number).
∗
P-values refer to comparisons between patients with EOSpA and LOSpA. Fisher exact test or Mann–Whitney U-test was used, as appropriate.
EOSpA=early-onset SpA, LOSpA= late-onset SpA, MCP=metacarpophalangeal, MRI=magnetic resonance imaging, PDUS=power Doppler ultrasound, PIP=proximal interphalangeal, SpA= spondyloarthritis.
Table 5
Multiple logistic regression analysis of selected variables in LOSpA
compared with EOSpA.
Variables P-value OR (95% CI)
Inflammatory back pain .021 0.288 (0.097–0.857)
Dactylitis .251 2.145 (0.584–7.878)
HLA B27 (+) .183 0.197 (0.014–2.754)
PDUS wrist synovitis .895 1.080 (0.344–3.393)
PDUS finger flexor tenosynovitis .803 1.214 (0.264–5.589)
PDUS wrist flexor tenosynovitis .892 1.099 (0.283–4.264)
PDUS finger collateral ligament .568 1.457 (0.401–5.302)
PDUS lateral collateral ligament .143 2.545 (0.710–9.118)
Odds ratio (OR), 95% confidence interval (95% CI), and P values are shown. EOSpA=early-onset
spondyloarthritis, HLA=human leukocyte antigen, LOSpA= late-onset spondyloarthritis, PDUS=
power Doppler ultrasound.
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4. Discussion
Our study clarified the clinical and laboratory differences
between LOSpA and EOSpA in a retrospective cohort of
Japanese patients. In addition, to the best of our knowledge,
this is the first study to describe in detail the differences in PDUS
findings in patients with EOSpA and LOSpA. Patients with
LOSpA had shorter disease duration before diagnosis, lower
prevalence of IBP, and HLA B27-positivity. In contrast, dactylitis
was more common in the LOSpA group than in the EOSpA
group, as were PDUS findings of articular synovitis (particularly
wrist synovitis), tenosynovitis, peritendinitis (particularly finger
and wrist flexor tenosynovitis), and enthesitis (particularly finger
collateral ligament and lateral collateral ligament).
The prevalence of HLAB27 in Japan is much lower than that in
other countries.[10] Further, a previous study in Japan showed an
entire of SpA prevalence of 0.04%, which is low compared with
that in other countries.[23] A study in Brazil showed that
individuals with EOSpA had a significantly higher frequency of
HLA B27-positivity than those with LOSpA, suggesting an
association between HLA B27 and early-onset disease.[14] A
possible implication of our findings is that the extremely low
prevalence of HLA B27 in Japan accounts for the lower
prevalence of early-onset disease among Japanese patients with
SpA.Moreover, the frequency of HLA B27-positivity is especially
high in individuals with AS compared with other forms of
SpA.[24] In addition, patients with PsA with axial involvement
reportedly had a significantly higher frequency of HLA B27-
positivity than those with only peripheral involvement, which
suggests an association between the presence of HLA B27 and
axial involvement.[25] Given these observations, Japanese
patients with SpA probably have a lower frequency of AS and
higher frequency of peripheral involvement because of the lower
prevalence of HLA B27 in the Japanese population compared
with that in other countries. Indeed, while the prevalence of AS is
estimated to be between 0.1% and 1.4%,[26] the estimated
prevalence of AS is much lower in Japan (0.0065%).[27] In our
study, 8 of 11 patients (72.7%) with AS were HLA B27-positive.
This frequency was comparable to that reported in the phase 3
trial of infliximab for AS in Japan (72.2%).[28] However, the
prevalence of HLA B27 was more than 90% among patients with
primary AS in Western European countries.[29] Although HLA
B27-positivity in Japanese patients with AS has not been clarified,
it may be lower than that in Western European countries.
Among 106 patients with SpA in Germany, 43.3% were
diagnosed with uSpA, 30.2%with AS, and 14.2%with PsA, thus
suggesting that uSpA is the most frequent type of SpA.[30] A
single-center cohort study in Japan showed that among patients
with SpA (average age, 43.4 years), 40 (of 59, 67.8%) were
classified as uSpA, 10 (16.9%) as AS, 6 (10.1%) as PsA, 2 (3.4%)
as IBD-related arthritis, and 1 (1.7%) as ReA excluding
palmoplantar pustular arthritis and SAPHO syndrome.[23]
Although average age was higher in our study, the proportion
of SpA subgroups was similar. Consistent with the findings of our
study, this study suggested a higher prevalence of uSpA in Japan
compared with that in other countries. Late-onset uSpA appears
to be comparatively more common than late-onset AS.[31–33] It is
important to recognize that even the elderly can develop SpA,
particularly uSpA, despite the very low prevalence of HLA B27.
Our study showed that wrist synovitis, finger and wrist flexor
tenosynovitis, and enthesitis of finger collateral ligament and
lateral collateral ligament were more commonly detected on
PDUS in the LOSpA group. PD signals of finger flexor tendon and
finger collateral ligament are occasionally observed in dactyli-
tis.[34] A previous report from Brazil showed that patients with
LOSpA had significantly fewer axial symptoms (ie, inflammatory
buttock pain, radiographic sacroiliitis, alternating buttock pain,
or hip involvement) and, conversely, a higher frequency of
peripheral symptoms (ie, peripheral arthritis and dactylitis).[14]
Other reports have also suggested that peripheral involvement is
more common in LOSpA.[14,31–33] Late-onset PsA is also more
associated with peripheral arthritis, with inflammatory edema of
the joints.[11,35–37] Consistent with a previous study,[14] we found
that patients with LOSpA had a shorter disease duration before
diagnosis. This is possibly because of a higher frequency of
peripheral symptoms in LOSpAwith readily visible physical signs
that can be more easily evaluated by physicians.[14]
The difficulty of definitively diagnosing SpA may also be a
reason for an apparently low prevalence of the disease in Japan. A
report from Canada showed that 11 of 35 patients initially
considered to have fibromyalgia were eventually diagnosed with
SpA.[38] On the other hand, 50% of women with AS in another
study also had fibromyalgia.[39] This suggests that the 2 diagnoses
may be confused with each other or that they may accompany
one another. Late-onset uSpA might be misdiagnosed as RA,
polymyalgia rheumatica (PMR), remitting seronegative symmet-
rical synovitis with pitting edema (RS3PE) syndrome, crystal-
induced arthritis, or osteoarthritis.[11] In a study of 20 patients
with late-onset uSpA who were HLA B27-positive, 6 appeared
with features mimicking RS3PE (ie, distal inflammation with
edema on the dorsum of the feet and/or hands) and 3 had a PMR-
like syndrome at onset.[40] Therefore, it is important to
distinguish other inflammatory rheumatic diseases from SpA.
Clinical features, such as tenderness of enthesis, arthritis of lower
limbs, and dactylitis are frequently detected in LOSpA. Thus,
these findings are useful for distinguishing SpA from other
rheumatic diseases. The use of PDUS early on to identify
enthesitis and dactylitis may, thus, be advisable to facilitate an
appropriate diagnosis in patients with peripheral symptoms.[8]
Although LOSpA has been considered rare,[11] each form of
SpA has been reported at the onset of the disease in older
patients.[12,14,41] In Japan, the aging rate is the highest than in
other countries, and the population ratio of people over 65 years
old was 26.6% in 2015. Our study was performed in an area with
a super-aging population, where individuals aged >65 years
account for 27.1% to 36.3% of the population.[42] In the future,
it is expected that the prevalence of LOSpA will increase as aging
progresses. The different characteristics between LOSpA and
EOSpA helps in not only making a correct diagnosis but also
selecting the optimal treatment, thus avoiding side effects caused
by unnecessary medication.
Our study has several limitations. First, there is no gold
standard for the diagnosis of SpA.[43] In our study, each patient
was observed for ≥1 year by rheumatologists who performed
comprehensive evaluations and excluded other rheumatic
diseases. Because the patients were evaluated in routine clinical
practice, PDUS findings may have introduced bias in the
interpretation of clinical diagnosis. Moreover, we determined
age at onset as the age when the patient presented the obvious
symptoms associated with SpA. However, if the symptoms are
insidious, it is possible that the patient may be grouped into
LOSpA. Second, our study was a single-center retrospective study
performed at a hospital in an area where the population is
progressively aging, which might have caused selection bias.
Because the sample size is small, there is a necessity to investigate
by increasing the number in a nationwide multicenter research.
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Finally, there are no established standard values to evaluate
disease activity in all forms encompassed by SpA. Therefore, we
did not include disease activity as a variable in our study.
Prospective multicenter studies are warranted to further compare
the clinical profiles of EOSpA and LOSpA, including disease
activity.
5. Conclusions
This is the first study to describe clinical differences between
EOSpA and LOSpA in Japan. In particular, we noted differences
in the PDUS findings between these 2 groups. We found that
patients with LOSpA had a shorter disease duration before
diagnosis, a lower prevalence of IBP orHLAB27-positivity, and a
higher prevalence of dactylitis, and peripheral PDUS findings
included articular synovitis (particularly wrist synovitis), teno-
synovitis or peritendinitis (particularly finger and wrist flexor
tenosynovitis), and enthesitis (particularly finger collateral
ligament and lateral collateral ligament). It is important to
distinguish LOSpA from other inflammatory diseases with
peripheral involvement such as RA, PMR, RS3PE syndrome,
and crystal-induced arthritis. Making a correct diagnosis of
LOSpA facilitates selection of the optimal treatment and possibly
reduces side effects caused by unnecessary medication.
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